Back to Directory
Lixisenatide
Metabolic & Weight ManagementShort-acting GLP-1 receptor agonist for type 2 diabetes, particularly effective for postprandial glucose.
Key Benefits
- ✓Controls postprandial glucose
- ✓Reduces A1C
- ✓Slows gastric emptying
- ✓Modest weight loss
- ✓Once-daily convenience
Dosing Information
Dosage Range
10-20 mcg
Frequency
Once daily before breakfast
Typical Duration
Ongoing
Detailed Protocol
Administered via subcutaneous injection once daily within one hour before first meal of the day. Start at lower dose and titrate after 2 weeks.
About Lixisenatide
Lixisenatide (Adlyxin) is a synthetic analog of exendin-4 and GLP-1 receptor agonist with a short duration of action. It particularly affects postprandial glucose by slowing gastric emptying. FDA-approved for type 2 diabetes.
Research Notes
FDA-approved in 2016. Clinical trials show good postprandial glucose control. Less weight loss than longer-acting GLP-1 agonists but effective for glycemic control.
Potential Side Effects
- •Nausea
- •Vomiting
- •Headache
- •Diarrhea
- •Dizziness
Always consult with a healthcare professional before starting any peptide therapy.